dihydroxyacetone phosphate has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, AL; Sheline, CT; Shi, C; Zhang, W; Zhu, J | 1 |
1 other study(ies) available for dihydroxyacetone phosphate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; Cell Death; Cells, Cultured; Cerebral Cortex; Dihydroxyacetone Phosphate; Disease Models, Animal; Drug Interactions; Embryo, Mammalian; Fructose-Bisphosphatase; Humans; Huntington Disease; Male; Matrix Metalloproteinase 16; Membrane Proteins; Membrane Transport Proteins; Mental Disorders; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Mice, Transgenic; NAD; Neurons; Niacinamide; Nitro Compounds; Oxidopamine; Parkinson Disease; Propionates; Pyruvic Acid; Rats; Rats, Long-Evans; Tyrosine 3-Monooxygenase; Zinc | 2013 |